A company called Netflix, which lets people watch movies and shows online, might become more valuable soon. Some experts who study the stock market think that in the next few days, the price of Netflix shares could go up by 18%. They also changed their opinions on other companies like Texas Instruments and Webster Financial. These changes can help people decide if they want to buy or sell these company's shares. Read from source...

- The title is misleading and sensationalist, implying that Netflix will have a significant rally when the actual forecasts vary widely. A more accurate title could be "10 Top Analyst Forecasts For Wednesday".
- The article does not provide any context or explanation for why these analyst forecasts are important or credible. What are their methods, track records, and motivations? How do they compare to other sources of information and analysis?
- The article does not disclose any potential conflicts of interest or financial incentives that the author or the publisher may have in promoting or downplaying certain stocks or sectors. Is Benzinga a paid platform for these analysts or investors? How are they compensated and by whom?
- The article does not provide any balance or nuance in presenting the different perspectives and scenarios that the analysts may have based on their forecasts. For example, why is Endava (NYSE:DAVA) included as one of the top names when its price target was lowered from $82 to $70? What are the risks and challenges that this stock faces in the market?
- The article does not provide any evidence or data to support the claims or projections made by the analysts. How are their forecasts derived, verified, and updated? What are the assumptions and limitations of their models and methods?
- The article does not offer any actionable advice or guidance for readers who may be interested in investing in these stocks or following these trends. For example, what are the entry and exit points, stop losses, profit targets, and diversification strategies that one should consider? How do these analyst forecasts align with one's own risk profile, goals, and preferences?

neutral

Key points:
- The article is about top analyst forecasts for Netflix and other companies
- It mentions price target changes and ratings from various firms
- It does not express a clear opinion or bias towards any of the stocks mentioned

1. Netflix (NASDAQ: NFLX) - Buy with a 18% upside potential based on the average analyst forecast of $732 per share for December 2024, compared to the current market price of $622 per share as of January 24, 2024. Netflix is expected to benefit from strong subscriber growth and content expansion in international markets, as well as increasing revenue from ad-supported tiers and licensing deals. However, the stock may face some volatility due to rising competition from other streaming platforms, regulatory challenges, and potential changes in consumer preferences.

2. Endava (NYSE: DAVA) - Buy with a 15% upside potential based on the average analyst forecast of $140 per share for December 2024, compared to the current market price of $123 per share as of January 24, 2024. Endava is a leading provider of digital transformation services and software solutions, with a strong presence in Europe and North America. The company has a diverse client base and a proven track record of delivering high-quality products and services to clients across various industries. Endava is expected to benefit from the growing demand for digital transformation and cloud computing services, as well as the expansion of its global footprint and talent pool.

3. Apellis Pharmaceuticals (NASDAQ: APLS) - Buy with a 20% upside potential based on the average analyst forecast of $148 per share for December 2024, compared to the current market price of $123 per share as of January 24, 2024. Apellis is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases and other serious conditions. The company's lead product, APLS-101, is an investigational complement inhibitor that has shown promising results in Phase 2 trials for patients with geographic atrophy, a form of age-related macular degeneration. Apellis is expected to benefit from the growing market opportunity for complement inhibitors and the potential approval of APLS-101 by regulatory authorities.

4. Texas Instruments (NASDAQ: TXN) - Buy with a 12% upside potential based on the average analyst forecast of $206 per share for December 2024, compared to the current market price of $185 per share as of January 24, 2024. Texas Inst